Your browser doesn't support javascript.
loading
HLA association with the susceptibility to anti-synthetase syndrome.
Remuzgo-Martínez, Sara; Atienza-Mateo, Belén; Ocejo-Vinyals, J Gonzalo; Pulito-Cueto, Verónica; Prieto-Peña, Diana; Genre, Fernanda; Marquez, Ana; Llorca, Javier; Mora Cuesta, Víctor M; Fernández, David Iturbe; Riesco, Laura; Ortego-Centeno, Norberto; Gómez, Nair Pérez; Mera, Antonio; Martínez-Barrio, Julia; López-Longo, Francisco Javier; Lera-Gómez, Leticia; Moriano, Clara; Díez, Elvira; Tomero, Eva; Calvo-Alén, Jaime; Romero-Bueno, Fredeswinda; Sanchez-Pernaute, Olga; Nuño, Laura; Bonilla, Gema; Grafia, Ignacio; Prieto-González, Sergio; Narvaez, Javier; Trallero-Araguas, Ernesto; Selva-O'Callaghan, Albert; Gualillo, Oreste; Martín, Javier; Cavagna, Lorenzo; Castañeda, Santos; Cifrian, José M; Renzoni, Elisabetta A; López-Mejías, Raquel; González-Gay, Miguel A.
Afiliación
  • Remuzgo-Martínez S; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Atienza-Mateo B; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain; 'López Albo' post-residency programme, Hospital Universitario Marqués de Valdecilla, S
  • Ocejo-Vinyals JG; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Pulito-Cueto V; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Prieto-Peña D; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Genre F; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Marquez A; Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain; Systemic Autoimmune Disease Unit, Hospital Universitario Clínico San Cecilio, Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain.
  • Llorca J; Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain.
  • Mora Cuesta VM; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Fernández DI; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Riesco L; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Ortego-Centeno N; Systemic Autoimmune Disease Unit, Hospital Universitario Clínico San Cecilio, Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain.
  • Gómez NP; Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
  • Mera A; Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
  • Martínez-Barrio J; Department of Rheumatology, Hospital General Universitario Gregorio-Marañón, Madrid, Spain.
  • López-Longo FJ; Department of Rheumatology, Hospital General Universitario Gregorio-Marañón, Madrid, Spain.
  • Lera-Gómez L; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Moriano C; Division of Rheumatology, Complejo Asistencial Universitario de León, León, Spain.
  • Díez E; Division of Rheumatology, Complejo Asistencial Universitario de León, León, Spain.
  • Tomero E; Department of Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain.
  • Calvo-Alén J; Rheumatology Division, Hospital Universitario Araba, Vitoria/Gasteiz, Alava, Spain.
  • Romero-Bueno F; Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Sanchez-Pernaute O; Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Nuño L; Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain.
  • Bonilla G; Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain.
  • Grafia I; Department of Autoimmune Diseases, Hospital Clínico de Barcelona, Universidad de Barcelona, Barcelona, Spain.
  • Prieto-González S; Department of Autoimmune Diseases, Hospital Clínico de Barcelona, Universidad de Barcelona, Barcelona, Spain.
  • Narvaez J; Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain.
  • Trallero-Araguas E; Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain.
  • Selva-O'Callaghan A; Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain.
  • Gualillo O; SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Santiago de Compostela, Spain.
  • Martín J; Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain.
  • Cavagna L; Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Castañeda S; Department of Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain.
  • Cifrian JM; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain; School of Medicine, Universidad de Cantabria, Santander, Spain.
  • Renzoni EA; Interstitial Lung Disease Unit, Royal Brompton Hospital, Imperial College, London, United Kingdom.
  • López-Mejías R; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: rlopezmejias78@gmail.com.
  • González-Gay MA; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain; School of Medicine, Universidad de Cantabria, Santander, Spain; Cardiovascular Pathoph
Joint Bone Spine ; 88(3): 105115, 2021 05.
Article en En | MEDLINE | ID: mdl-33301929
OBJECTIVE: To investigate the human leukocyte antigen (HLA) association with anti-synthetase syndrome (ASSD). METHODS: We conducted the largest immunogenetic HLA-DRB1 and HLA-B study to date in a homogeneous cohort of 168 Caucasian patients with ASSD and 486 ethnically matched healthy controls by sequencing-based-typing. RESULTS: A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed (26.2% versus 12.2%, P=1.56E-09, odds ratio-OR [95% confidence interval-CI]=2.54 [1.84-3.50] and 21.4% versus 5.5%, P=18.95E-18, OR [95% CI]=4.73 [3.18-7.05]; respectively). Additionally, HLA-DRB1*07:01 allele was significantly decreased in patients with ASSD compared to controls (9.2% versus 17.5%, P=0.0003, OR [95% CI]=0.48 [0.31-0.72]). Moreover, a statistically significant increase of HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative patients with ASSD was observed (31.8% versus 15.5%, P=0.001, OR [95% CI]=2.54 [1.39-4.81]). Similar findings were observed when HLA carrier frequencies were assessed. The HLA-DRB1*03:01 association with anti-Jo-1 was unrelated to smoking history. No HLA differences in patients with ASSD stratified according to the presence/absence of the most representative non-anti-Jo-1 anti-synthetase autoantibodies (anti-PL-12 and anti-PL-7), arthritis, myositis or interstitial lung disease were observed. CONCLUSIONS: Our results support the association of the HLA complex with the susceptibility to ASSD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ligasas / Miositis Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Joint Bone Spine Asunto de la revista: REUMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ligasas / Miositis Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Joint Bone Spine Asunto de la revista: REUMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Francia